Novartis Clozaril “Dear Doctor” letter
Executive Summary
Novartis issues "Dear Health Care Provider" letter April 1 on the diabetes class warning for atypical antipsychotics. Novartis added class warning to Clozaril (clozapine) labeling Dec. 23. AstraZeneca (Seroquel), Lilly (Zyprexa) and Bristol-Myers Squibb (Abilify) issued similar letters (1"The Pink Sheet" April 5, 2004, p. 32). FDA requested that sponsors revise labeling in September 2003 (2"The Pink Sheet" Sept. 22, 2003, p. 20)...